Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 7, Issue 8, Pages 1275-1280Publisher
INFORMA HEALTHCARE
DOI: 10.1517/14712598.7.8.1275
Keywords
dendritic cell; immunotherapy; prostate cancer; prostatic acid phosphatase; Provenge
Ask authors/readers for more resources
Dendritic cells are deficient both in number and function in patients with cancer. Loaded dendritic cell therapies aim to overcome this deficiency by delivering antigens to antigen-presenting cells under ex vivo conditions, improving dendritic cell function. APC8015 (Provenge((R)); Dendreon Corp., Seattle, WA) is a novel immunotherapeutic, which consists of autologous dendritic cells pulsed ex vivo with PA2024, a recombinant fusion protein consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase, as an immunogenic agent. A Phase III randomized clinical trial has demonstrated a survival benefit in patients with metastatic hormone-refractory prostate cancer. This review summarizes the clinical trials using APC801 5 in prostate cancer and discusses its future role in the treatment of prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available